SGI
VRTX icon

Summit Global Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Summit Global Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.57M Buy
7,182
+3,286
+84% +$1.46M 0.19% 62
2026
Q1 		$1.74M Sell
3,896
-308
-7% -$144K 0.1% 105
2025
Q4 		$1.91M Sell
4,204
-770
-15% -$332K 0.11% 99
2025
Q3 		$1.95M Buy
4,974
+1,062
+27% +$444K 0.11% 107
2025
Q2 		$1.74M Buy
3,912
+342
+10% +$158K 0.1% 128
2025
Q1 		$1.73M Sell
3,570
-1,407
-28% -$656K 0.13% 99
2024
Q4 		$2M Sell
4,977
-813
-14% -$377K 0.13% 130
2024
Q3 		$2.69M Sell
5,790
-3,829
-40% -$1.84M 0.17% 106
2024
Q2 		$4.51M Sell
9,619
-32,290
-77% -$14M 0.3% 71
2024
Q1 		$17.5M Sell
41,909
-32,679
-44% -$13.8M 1.3% 10
2023
Q4 		$30.3M Buy
74,588
+23,118
+45% +$8.54M 1.99% 7
2023
Q3 		$17.9M Buy
51,470
+46
+0.1% +$16.1K 1.19% 14
2023
Q2 		$18.1M Sell
51,424
-17,238
-25% -$5.81M 1.2% 11
2023
Q1 		$21.6M Buy
68,662
+273
+0.4% +$81.9K 1.67% 6
2022
Q4 		$19.7M Sell
68,389
-4,619
-6% -$1.41M 1.67% 7
2022
Q3 		$21.1M Sell
73,008
-7,841
-10% -$2.26M 1.95% 5
2022
Q2 		$22.8M Sell
80,849
-9,713
-11% -$2.6M 2.01% 3
2022
Q1 		$23.6M Sell
90,562
-4,482
-5% -$1.06M 1.74% 5
2021
Q4 		$20.9M Buy
+95,044
New +$18.5M 1.34% 17
2021
Q3 		– Sell
-5,007
Closed -$986K – 574
2021
Q2 		$986K Sell
5,007
-45,447
-90% -$9.51M 0.06% 235
2021
Q1 		$10.8M Buy
50,454
+20,657
+69% +$4.54M 0.69% 35
2020
Q4 		$7.04M Buy
29,797
+27,731
+1,342% +$6.36M 0.7% 33
2020
Q3 		$562K Sell
2,066
-18
-0.9% -$4.97K 0.06% 178
2020
Q2 		$605K Buy
+2,084
New +$565K 0.07% 175

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Summit Global Investments's VRTX Position: Q2 2026 in Review

Summit Global Investments increased its Vertex Pharmaceuticals (VRTX) stake by 84% in Q2 2026, buying an estimated $1.46M and bringing the position to 7,182 shares worth $3.57M. The position accounts for 0.19% of the portfolio, ranked #62.

Summit Global Investments first reported a position in VRTX in Q2 2020 and has held it in 24 quarters since. The position peaked at $30.3M in Q4 2023. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Summit Global Investments held 7,182 shares of Vertex Pharmaceuticals worth $3.57M as of Q2 2026.
  • Summit Global Investments bought 3,286 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.46M.
  • Vertex Pharmaceuticals made up 0.19% of Summit Global Investments's portfolio in Q2 2026, its #62 holding.
  • Summit Global Investments first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Summit Global Investments's Vertex Pharmaceuticals position peaked at $30.3M in Q4 2023.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Summit Global Investments's 13F filing for Q2 2026, filed 3 Aug 2026.